Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 To Treat Small-Volume Ovarian, Peritoneal, Fallopian Tube Cancer - Related Studies

Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 To Treat Small-Volume Ovarian, Peritoneal, Fallopian Tube Cancer

This study has been completed.

Study NCT00074867. Last updated on November 6, 2006. Information provided by Pfizer

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Ovarian Neoplasms
		Peritoneal Neoplasms
		Fallopian Tube Neoplasms

2	Additional conditions recognized in this trial
		Neoplasms

3	More general conditions related to this trial
		Abdominal Neoplasms
		Adnexal Diseases
		Digestive System Diseases
		Digestive System Neoplasms
		Endocrine Gland Neoplasms
		Endocrine System Diseases
		Fallopian Tube Diseases
		Genital Diseases, Female
		Genital Neoplasms, Female
		Gonadal Disorders
		Neoplasms by Site
		Ovarian Diseases
		Peritoneal Diseases
		Urogenital Neoplasms

4	Interventions listed in this trial
		CP-547,632

5	Sponsors listed in this trial
		Pfizer